A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
about
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAnti-angiogenesis in prostate cancer: knocked down but not outIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisNSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesisAngiogenesis inhibitors in the treatment of prostate cancer.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.Angiogenesis inhibition in prostate cancer: current uses and future promises.New knowledge of the mechanisms of sorafenib resistance in liver cancerA phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerA randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.MET and VEGF: synergistic targets in castration-resistant prostate cancerTargeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.Castration-resistant prostate cancer: mechanisms, targets, and treatment.Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathwaysEmerging targeted therapies for castration-resistant prostate cancer.Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerFeasibility of measuring prostate perfusion with arterial spin labelingInefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewThe multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cellsCurrent management of prostate cancer: dilemmas and trialsVEGF inhibitors and prostate cancer therapyAnti-angiogenesis approach to genitourinary cancer treatment.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Pazopanib: therapeutic developments.Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?Docetaxel-based combination therapy for castration-resistant prostate cancer.Current treatment strategies for castration-resistant prostate cancerThe changing therapeutic landscape of castration-resistant prostate cancer.Targeting angiogenesis for the treatment of prostate cancer.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.Phase II study of sunitinib in men with advanced prostate cancer.Angiogenesis inhibitors in the treatment of prostate cancer
P2860
Q24647897-941C71E8-EB30-4929-B59B-C142AC717406Q26851177-1A98C11C-FA86-4CBC-97BA-DD5549CFA2D2Q26851183-86E70D7F-B90F-4D02-8601-3B87D8C25A9BQ27003304-48803F20-1A91-42E8-9065-513288394D6BQ27320669-460E7BF8-C9FC-4411-B061-30B27F6556DBQ33611121-D54BDDB3-8E37-4D55-A7BD-35B55A51B824Q33633424-0E5E2EB3-C60F-4EFD-9F8D-2679C61FE149Q33638830-05CBA80F-7F46-406D-8BC1-A27279FB83D9Q33652297-A927FA0F-DCA6-41A1-9375-C3B6BBA3D5EDQ33759933-3E34DEB9-7DA5-4AFA-A1B1-7E69920B5AE3Q34657338-D3FD7BC7-C123-4886-9AD2-2C93C3B0CAAFQ35034020-93C7390A-1F76-4BE2-88BD-B13175ED47B2Q35508739-E855208A-422E-4CCF-B7B1-F37206126400Q35575488-3E0580C9-1ADC-467E-BE8E-ACA3E8ADFEFAQ35723957-CA52D268-ADB7-43E4-A2CA-2E7C7F7A6551Q35864027-A1E4BC12-CFE2-42E2-A503-D3B9C8A6B906Q35963384-55447DBB-B51C-4BAC-B2A4-D39BDB800866Q35999255-5C7A523A-ED31-46C1-AC30-27125E90A472Q36105720-D7F7ED08-5CC3-43DE-A59D-11887CC42467Q36166836-E42A8552-A57B-4C31-9D93-84C3D9CE04A1Q36269104-DC44FD74-8312-4960-A602-1055C1EBF211Q36270115-5909DCED-7136-41C9-A8F6-3B7B56CB4CF1Q37084695-BA909512-77BA-422F-AF13-34632782FC45Q37102535-EB1FC73B-492A-49D6-BF7C-48D40A97D0EAQ37264085-134DB699-F441-4055-BBE3-6DFB86E68AB5Q37354411-F92FEC42-F72F-4A56-93CC-7143D708A8F1Q37575815-EC1EEB99-C88C-403D-8105-197D0DAD0DA9Q37642770-0911F4BD-7741-48C7-96AF-3B667447B674Q37688711-DB9B7B12-434E-4C03-A87A-03D184EEA48EQ37721016-F7C0F96F-0C48-4B86-8C4B-45C36A56BFF0Q37860950-EAFC7A23-66D6-45DB-A95A-CA0E40C5A197Q37913983-23094274-6FF9-4FE2-AC48-ADB0AA0F1969Q37993137-F51EB1AF-A528-4D07-8958-8D8F493684DBQ38103397-87161A79-EAFE-499A-A05A-DF2D5B60FB8CQ38723404-5225A9FC-C148-4E0C-8FFB-B6CD02432C12Q38940292-C2A6D617-6115-4B3E-A2C5-5953160C2139Q39251637-BC45A542-A770-410B-BFBC-FC94EF713E10Q39983597-1EE04794-74F5-4561-BB16-B03EE80619F8Q57139434-9922EC64-CADF-4EF7-898A-CE2C1736C059
P2860
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@ast
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@en
type
label
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@ast
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@en
prefLabel
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@ast
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@en
P2093
P2860
P50
P356
P1476
A clinical phase II study with ...... Anticancer Drug Research-EWIV.
@en
P2093
A-R Hanauske
C Dittrich
I Burkholder
M Scheulen
S Steinbild
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604064
P407
P577
2007-11-27T00:00:00Z
P5875
P6179
1006508963